SCHEMBL5414130

SCHEMBL5414130

NC(=O)c1ccc(F)cc1Cl.O=S(=O)(O)/C=C/c1cc(Cl)cc(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 5/20 0.40
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
MAOB P27338 1/20 0.39
HPGD P15428 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
KMT2A Q03164 2/20 0.38
PYGL P06737 3/20 0.37
HTR2A P28223 2/20 0.37
HTR2C P28335 2/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5420983 0.91 PTGES2 (0.50) PTGES2KDM4EPOLBMAOBNPC1
SCHEMBL27739105 0.91 PTGES2 (0.50) PTGES2KDM4EPOLBMAOBNPC1
SCHEMBL28775723 0.91 MAOB (0.49) PTGES2KDM4EMAOBHPGDNPC1
SCHEMBL5411555 0.91 MAOB (0.49) PTGES2KDM4EMAOBHPGDNPC1
SCHEMBL5418978 0.88 HTR2A (0.43) PTGES2KDM4EPOLBMAOBHPGD
SCHEMBL27717765 0.88 HTR2A (0.43) PTGES2KDM4EPOLBMAOBHPGD
SCHEMBL5407438 0.87 PTGES2 (0.49) PTGES2MAOBHPGDPYGLHTR2A
SCHEMBL4256668 0.84 ALOX5 (0.36) PTGES2MAOBHPGDNPC1RAB9A
SCHEMBL28771576 0.84 PTGES2 (0.47) PTGES2MAOBHTR2AHTR2CCA12
SCHEMBL5409694 0.84 PTGES2 (0.47) PTGES2MAOBHTR2AHTR2CCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 PTGES2 3551/4885KDM4E 1941/4885POLB 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.